Literature DB >> 33568112

A patient perspective of complementary and integrative medicine (CIM) for migraine treatment: a social media survey.

Deena E Kuruvilla1, Amit Mehta2, Nidhi Ravishankar2, Robert P Cowan3.   

Abstract

To survey persons with migraine who use social media about Complementary and Integrative Medicine (CIM) for the treatment of migraine.
BACKGROUND: CIM encompasses medical treatments that are not part of but are used in concert with mainstream medicine. Between 28 and 82% of people with migraine use non-drug approaches, and approximately 50% of people with migraine do not discuss non-drug treatments with their healthcare providers (HCPs). It is important for providers to be conversant with CIM treatments and the available evidence-based data. To further this effort, people with migraine were surveyed directly through social media to identify CIM practices in which they engage.
METHODS: In collaboration with the American Migraine foundation (AMF) and Yakkety Yak, a digital marketing agency, we conducted a cross-sectional survey study. Participants were recruited from the Move Against Migraine (MAM) Facebook group which has 20,000+ members. The goals of the survey were to assess the attitudes toward CIM among this group, to identify which CIM modalities are being used and to determine what patients considered to be the most effective CIM modalities. While Yakkety Yak posted the survey link on the group page, the survey itself was hosted on Qualtrics, a confidential survey service.
RESULTS: 372 MAM members (approximately 2%) responded to the questionnaire, of which 335 reported using CIM; between 114 and 139 (34-42%) found CIM modalities to be at least mildly effective. Of note, 164 (49%) reported using cannabis derivatives or cannabinoids, specifically with, 64/164 (39%) reporting that cannabis was not effective for them.
CONCLUSIONS: This study provides an initial investigation into the demographic and practice patterns of migraine patients who use CIM. While this sampling may not reflect CIM use across all individuals with migraine, it does strongly suggest the need for better education on the role of, and evidence for, CIM among headache care providers, and the need to ask patients specifically about their use of and interest in CIM.

Entities:  

Year:  2021        PMID: 33568112      PMCID: PMC7877058          DOI: 10.1186/s12906-021-03226-0

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  18 in total

1.  Complementary and alternative medicine use among US adults with common neurological conditions.

Authors:  Rebecca Erwin Wells; Russell S Phillips; Steven C Schachter; Ellen P McCarthy
Journal:  J Neurol       Date:  2010-06-11       Impact factor: 4.849

2.  Guidelines for trials of behavioral treatments for recurrent headache: purpose, process, and product.

Authors:  Donald B Penzien
Journal:  Headache       Date:  2005-05       Impact factor: 5.887

3.  Reasons for and perceived benefits of utilizing complementary and alternative medicine in U.S. adults with migraines/severe headaches.

Authors:  Taeho Greg Rhee; Ila M Harris
Journal:  Complement Ther Clin Pract       Date:  2017-12-06       Impact factor: 2.446

4.  Complementary and alternative medicine use among adults with migraines/severe headaches.

Authors:  Rebecca Erwin Wells; Suzanne M Bertisch; Catherine Buettner; Russell S Phillips; Ellen P McCarthy
Journal:  Headache       Date:  2011-06-07       Impact factor: 5.887

5.  Gender Differences in the Use of Complementary and Alternative Medicine and Their Association With Moderate Mental Distress in U.S. Adults With Migraines/Severe Headaches.

Authors:  Taeho Greg Rhee; Ila M Harris
Journal:  Headache       Date:  2016-11-25       Impact factor: 5.887

6.  Evaluating the effectiveness of a mnemonic to guide staff when providing patient education to autologous hematopoietic stem cell transplant patients.

Authors:  Cheryl Page; Charissa Cordon; Jiahui Wong
Journal:  Can Oncol Nurs J       Date:  2019-04-01

7.  Use of complementary therapies in patients with cardiovascular disease.

Authors:  Gloria Y Yeh; Roger B Davis; Russell S Phillips
Journal:  Am J Cardiol       Date:  2006-07-07       Impact factor: 2.778

8.  Degradation of endocannabinoids in chronic migraine and medication overuse headache.

Authors:  L M Cupini; C Costa; P Sarchielli; M Bari; N Battista; P Eusebi; P Calabresi; M Maccarrone
Journal:  Neurobiol Dis       Date:  2008-02-01       Impact factor: 5.996

9.  Variations in the cannabinoid receptor 1 gene predispose to migraine.

Authors:  Gabriella Juhasz; Judit Lazary; Diana Chase; Emma Pegg; Darragh Downey; Zoltan G Toth; Kathryn Stones; Hazel Platt; Krisztina Mekli; Antony Payton; Ian M Anderson; J F William Deakin; Gyorgy Bagdy
Journal:  Neurosci Lett       Date:  2009-06-17       Impact factor: 3.046

10.  Complementary and alternative medicine use among adults and children: United States, 2007.

Authors:  Patricia M Barnes; Barbara Bloom; Richard L Nahin
Journal:  Natl Health Stat Report       Date:  2008-12-10
View more
  3 in total

1.  Medical Cannabis for the Treatment of Migraine in Adults: A Review of the Evidence.

Authors:  Babasola O Okusanya; Breanne E Lott; John Ehiri; Jean McClelland; Cecilia Rosales
Journal:  Front Neurol       Date:  2022-05-30       Impact factor: 4.086

2.  Complementary and integrative medicine perspectives among veteran patients and VHA healthcare providers for the treatment of headache disorders: a qualitative study.

Authors:  Deena E Kuruvilla; Hayley Lindsey; Amy S Grinberg; Roberta E Goldman; Samantha Riley; Sean Baird; Brenda T Fenton; Jason J Sico; Teresa M Damush
Journal:  BMC Complement Med Ther       Date:  2022-01-25

3.  Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).

Authors:  Deena E Kuruvilla; Joseph I Mann; Stewart J Tepper; Amaal J Starling; Gregory Panza; Michael A L Johnson
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.